Geron (GERN) Total Current Liabilities (2010 - 2026)
Geron's (GERN) quarterly Total Current Liabilities came in at $70.3 million in Q2 2026, up 9.41% year-over-year from $64.3 million in Q2 2025, and down 4.4% quarter-over-quarter from $73.6 million in Q1 2026.
Analysis
Geron (GERN) Total Current Liabilities (2010 - 2026) Analysis & Trends
Geron has disclosed Total Current Liabilities across 17 years of filings, most recently posting $70.3 million for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 9.41% year-over-year to $70.3 million; the TTM figure through Jun 2026 stood at $70.3 million (up 9.41% YoY), while the FY2025 annual figure was $111.5 million, up 26.32% from the prior year.
- Total Current Liabilities came in at $70.3 million for Q2 2026 at Geron, down from $73.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $137.9 million in Q3 2024 to a low of $43.9 million in Q1 2023.
- Average Total Current Liabilities over 5 years is $82.8 million, with a median of $79.8 million recorded in 2022.
- Year-over-year, Total Current Liabilities soared 180.47% in 2024 and slumped 48.82% in 2025.
- Over 5 years, Total Current Liabilities stood at $76.7 million in 2022, then soared by 40.91% to $108.1 million in 2023, then retreated by 18.3% to $88.3 million in 2024, then increased by 26.32% to $111.5 million in 2025, then slumped by 36.95% to $70.3 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $70.3 million in Q2 2026, $73.6 million in Q1 2026, and $111.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 70.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 70.33 Mn |
| Mar 31, 2026 | 73.57 Mn |
| Dec 31, 2025 | 111.54 Mn |
| Sep 30, 2025 | 87.71 Mn |
| Jun 30, 2025 | 64.28 Mn |
| Mar 31, 2025 | 63.03 Mn |
| Dec 31, 2024 | 88.30 Mn |
| Sep 30, 2024 | 137.93 Mn |
| Jun 30, 2024 | 103.54 Mn |
| Mar 31, 2024 | 123.16 Mn |
| Dec 31, 2023 | 108.07 Mn |
| Sep 30, 2023 | 89.39 Mn |
| Jun 30, 2023 | 72.57 Mn |
| Mar 31, 2023 | 43.91 Mn |
| Dec 31, 2022 | 76.69 Mn |
| Sep 30, 2022 | 82.81 Mn |
| Jun 30, 2022 | 46.88 Mn |
| Mar 31, 2022 | 46.63 Mn |
| Dec 31, 2021 | 45.52 Mn |
| Sep 30, 2021 | 38.47 Mn |